Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination

Brendan Moran1, Dario Baratti, Tristan D Yan

  • 1Colorectal Research Unit, North Hampshire Hospital, Basingstoke, Hampshire, UK.

Insights

Cytoreductive surgery (CRS) combined with perioperative loco-regional chemotherapy (PLC) offers improved survival for pseudomyxoma peritonei (PMP). Experts reached consensus on treatment indications and methodology, supporting this approach for PMP management.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Pseudomyxoma peritonei (PMP) is a rare appendiceal tumor with limited survival and no cure.
  • Current treatments offer limited long-term survival prospects.

Purpose of the Study:

  • To summarize literature on cytoreductive surgery (CRS) and perioperative loco-regional chemotherapy (PLC) for PMP.
  • To discuss and reach consensus on controversial PMP management issues.

Main Methods:

  • Literature review on CRS and PLC for PMP.
  • Web-based expert voting system to discuss indications and methodology.
  • Presentation of results at the Fifth International Workshop on Peritoneal Surface Malignancy.

Main Results:

  • Experts agreed prospective trials support improved survival with CRS and PLC compared to historical controls.
  • High consistency among experts on controversial methodological questions.
  • Agreement with existing literature findings on PMP management.

Conclusions:

  • The combined CRS and PLC approach is supported by evidence for improved PMP survival.
  • Expert consensus was reached on key aspects of PMP treatment methodology and indications.